UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 39

of 'Systemic treatment for metastatic breast cancer: General principles'

39
TI
Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays.
AU
Weisenthal LM, Kern DH
SO
Oncology (Williston Park). 1991;5(9):93.
 
In the opinion of the authors, good medical practice demands the avoidance of ineffective therapies and good cancer chemotherapy generally demands the avoidance of inactive drugs. The authors present their viewpoint that randomized trials are not required to prove that physicians should not administer inactive drugs and that existing cell culture assays are acceptably accurate in identifying inactive drugs. They describe and advocate the use of two such tests to aid in choosing between different forms of therapy that would otherwise be equally acceptable in the absence of test information. Strengths, weaknesses, and applications of the assays are discussed.
AD
Oncotech, Inc. Irvine, California.
PMID